ProQR Therapeutics N.V. announced changes to its management team and key hires: Aniz Girach, MD, is joining ProQR as Chief Medical Officer and will be reporting to David Rodman, MD, Executive Vice President of R&D. Aniz is an experienced ophthalmologist and has over 20 years of experience in the biotech industry focusing on retinal diseases. Most recently, Aniz worked as the Chief Medical Officer for Nightstar Therapeutics where he oversaw the development of gene therapies for inherited retinal disorders. Tiffany Burt is joining the company in the role of Vice president, Head of Commercial. Tiffany Burt has more than 20 years of global commercial experience spanning across all phases of pre-launch market development and global biopharmaceutical commercialization including multiple rare therapeutic areas. She has been involved with the launch of 8 different products. Prior to joining ProQR, she served as Vice President, Marketing at Verastem Oncology where she built the marketing organization including key platforms and programs across the commercial organization launching Duvelisib in 2018. Lisa A. Hayes will join ProQR as Vice President of Investor Relations and Corporate Communications and brings over 20 years of experience in the healthcare space. Lisa joins ProQR from Celgene, where she was most recently Senior Director of Investor Relations. Smital Shah joined ProQR in 2014 as Chief Financial Officer and is now promoted to Chief Business and Financial Officer. Prior to ProQR, Smital held management and leadership positions in biopharma companies and investment banking. Most recently she was at Gilead Sciences, where she managed their multi-billion dollar debt, cash and investment portfolios. At year-end 2018 both René Beukema, Chief Corporate Development Officer, General Counsel and management board member and Robert Cornelisse, Chief People and Organization, will retire from their roles at ProQR. René and Robert will not be replaced in the management team.